Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/AIDS.3.011
Pre-exposure Prophylaxis (PrEP) for HIV Infection and New Sexually Transmitted Infections: A Win-Win Opportunity?
François Aubin1,2,*, Clélia Vanhaecke3, Christine Drobacheff1, Fabien Pelletier1, Manuelle Viguier3
- 1Department of Dermatology, CHU and UFR Health, University of Franche-Comté, Besancon, France
- 2INSERM UMR 1098, University of Franche-Comté, Besancon, France
- 3Department of Dermatology, Center for Information, Screening and Diagnosis (CeGIDD), CHU, Reims, France
Corresponding Author
François Aubin, francois.aubin@univ-fcomte.fr
Received Date: December 18, 2020
Accepted Date: January 25, 2021
Aubin F, Vanhaecke C, Drobacheff C, Pelletier F, Viguier M. Pre-Exposure Prophylaxis (PrEP) for HIV Infection and New Sexually Transmitted Infections: A Win-Win Opportunity? J AIDS HIV Treat. 2021; 3(1): 1-3.
Copyright: © 2021 Aubin F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Socio-Demographic Characteristics of Newly Diagnosed People Living with HIV Initiating Antiretroviral Treatment at the Adult Day Hospital of Bobo-Dioulasso Over a Five-year Period
Background: HIV infection is a major public health problem in sub-Saharan Africa, particularly in Burkina Faso. This study aimed to describe the socio-demographic characteristics of newly person living with HIV initiating antiretroviral treatment at the Adult Day Hospital of Bobo-Dioulasso over a five-year period. Materials and methods: A descriptive cross-sectional study was conducted from 1 January 2016 to 31 December 2020 at the Adult Day Hospital of Bobo-Dioulasso. People newly diagnosed with HIV after confirmatory testing and initiating antiretroviral therapy were included in this study.
The Dual Role of Macrophages during Hepatitis B Infection
Hepatitis B virus (HBV) chronically infects more than 250 million individuals worldwide and is responsible for more than 800,000 deaths per year by promoting end-stage liver diseases, among which decompensated cirrhosis and hepatocellular carcinoma (HCC) (WHO, July 2020) are prominent. Studies performed in chimpanzees or in animalversion of HBV (woodchuck HBV: WHBV) highlighted the lack of immune responses against the virus upon primary infection.
What Can Go Wrong When Applying Immune Modulation Therapies to Target Persistent Bacterial Infections
Antibiotics can treat the acute phase of a disease, but often do not completely clear the etiologic agent, allowing the pathogen to establish persistent infection that can revive the disease in a frustrating recurrence of infection. The mechanisms that control chronic bacterial infections are complex and involve pathogen adaptations that favor survival from both host immune responses and antibiotic bactericidal activity.
Tenofovir at the Crossroad of the Therapy and Prophylaxis of HIV and HBV Infections
Tenofovir, alias (R)-PMPA, was first divulged as an anti- HIV agent in 1993 [1]. That it would in 2012, become the first antiretroviral agent, approved by the US FDA (Food and Drug Administration) to prevent HIV infection, could have been predicted from the findings of Tsai et al.
Archives of Gastroenterology Research: A Message from Prof. Dr. Rolf Teschke (Editor-in-Chief)
As the new editor-in-chief of Archives of Gastroenterology Research (AGR) I cordially welcome all current readers of AGR and future contributors to AGR. Together with my editorial team of AGR we encourage scientists and clinicians involved in the care of patients with gastrointestinal diseases to submit their interesting reports to AGR with the aim to be published following fair evaluation by external peer reviewers